Sarepta Therapeutics (SRPT) vs Trevi Therapeutics (TRVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Trevi Therapeutics (TRVI) has outperformed Sarepta Therapeutics (SRPT) over the past year, gaining 37.6% versus a loss of 24.3%. Over five years, TRVI leads with a +918.6% price change compared with -79.2% for SRPT. Trevi Therapeutics is the larger company by market cap ($1.87 billion vs $1.85 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SRPT | TRVI |
|---|---|---|
| Share price | $17.50 | $13.14 |
| Market cap | $1.85B | $1.87B |
| 1-day change | +1.10% | -0.30% |
| YTD return | -18.68% | +4.95% |
| 1-year return | -24.31% | +37.59% |
| 5-year return | -79.21% | +918.60% |
| Forward P/E | 7.26 | — |
| EPS (TTM) | $-1.57 | $-0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $24.68 | $20.22 |
| 52-week low | $14.68 | $9.28 |
| Distance from 52-week high | -29.09% | -35.01% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +24.17% | +114.46% |
| Average volume | 2.99M | 1.91M |
| Shares outstanding | 105.63M | 142.48M |
| Employees | 835 | 34 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TRVI has outperformed SRPT by 61.9 percentage points over the past year.
About Sarepta Therapeutics
SRPT stock →Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Health Care · Biotechnology: Pharmaceutical Preparations · 835 employees
About Trevi Therapeutics
TRVI stock →Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
SRPT vs TRVI FAQ
Which is bigger, Sarepta Therapeutics or Trevi Therapeutics?
Trevi Therapeutics (TRVI) is larger, with a market capitalization of $1.87B compared with $1.85B for Sarepta Therapeutics (SRPT).
Which stock has performed better over the past year, SRPT or TRVI?
TRVI returned +37.59% over the past 12 months, compared with -24.31% for SRPT (price return, excluding dividends). Past performance does not predict future results.
Are Sarepta Therapeutics and Trevi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.